{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:52:12Z","timestamp":1792047132519,"version":"4.4.0"},"reference-count":81,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T00:00:00Z","timestamp":1605744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:p>\n                    Cefiderocol (CFDC), (formerly S\u2010649266), is a novel injectable siderophore cephalosporin developed by Shionogi &amp; Co., Ltd., with potent in vitro activity against Gram\u2010negative pathogens including multidrug\u2010resistant (MDR) Enterobacteriaceae and non\u2010fermenting organisms, such as\n                    <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                    ,\n                    <jats:italic>Acinetobacter baumannii<\/jats:italic>\n                    ,\n                    <jats:italic>Burkholderia cepacia<\/jats:italic>\n                    , and\n                    <jats:italic>Stenotrophomonas maltophilia<\/jats:italic>\n                    . Characterized by its siderophore catechol\u2010moiety, CFDC uses a \u201ctrojan\u2010horse approach\u201d to navigate through the bacterial periplasmic space, thus evading various beta\u2010lactam degrading enzymes and other mechanisms of resistance present in Gram\u2010negative bacteria. More specifically in carbapenem\u2010resistant Enterobacteriaceae, CFDC has been shown to have activity against extended spectrum beta\u2010lactamases (ESBLs), such as CTX\u2010type, SHV\u2010type, and TEM\u2010type, as well as the Ambler classes of beta\u2010lactamases, including class A (KPC), class B (NDM, IMP, and VIM), class C (AmpC), and class D (OXA, OXA\u201024, OXA\u201048, and OXA\u201048\u2010like). In addition to the strong activity that CFDC has been shown to have against MDR\n                    <jats:italic>P.\u00a0aeruginosa<\/jats:italic>\n                    , it has also displayed activity against the OXA\u201023, OXA\u201024, and OXA\u201051, beta\u2010lactamases commonly found in MDR\n                    <jats:italic>A.\u00a0baumannii<\/jats:italic>\n                    . Cefiderocol was recently approved by the US Food and Drug Administration (FDA) for use in complicated urinary tract infections (cUTI), including pyelonephritis, for use in patients 18\u00a0years or older with limited or no alternative options for treatment, and is currently being evaluated in a phase III trial for use in nosocomial pneumonia caused by Gram\u2010negative pathogens. The unique features and enhanced activity of CFDC suggest that it is likely to serve as a viable therapeutic option in the treatment of MDR Gram\u2010negative infections. The purpose of this review is to provide an overview of previously published literature explaining CFDC\u2019s pharmacology, pharmacokinetic \/ pharmacodynamic (PK \/ PD) properties, microbiologic activity, resistance mechanisms, safety parameters, dosing and administration, clinical data, and potential place in therapy.\n                  <\/jats:p>","DOI":"10.1002\/phar.2476","type":"journal-article","created":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T16:51:16Z","timestamp":1602953476000},"page":"1228-1247","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug\u2010Resistant Gram\u2010Negative Pathogens"],"prefix":"10.1002","volume":"40","author":[{"given":"Jacinda C.","family":"Abdul\u2010Mutakabbir","sequence":"first","affiliation":[{"name":"Anti\u2010Infective Research Laboratory Department of Pharmacy Practice Eugene Applebaum College of Pharmacy and Health Sciences Wayne State University Detroit Michigan USA"},{"name":"Department of Pharmacy Practice Loma Linda University School of Pharmacy Loma Linda California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Alosaimy","sequence":"additional","affiliation":[{"name":"Anti\u2010Infective Research Laboratory Department of Pharmacy Practice Eugene Applebaum College of Pharmacy and Health Sciences Wayne State University Detroit Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Morrisette","sequence":"additional","affiliation":[{"name":"Anti\u2010Infective Research Laboratory Department of Pharmacy Practice Eugene Applebaum College of Pharmacy and Health Sciences Wayne State University Detroit Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razieh","family":"Kebriaei","sequence":"additional","affiliation":[{"name":"Anti\u2010Infective Research Laboratory Department of Pharmacy Practice Eugene Applebaum College of Pharmacy and Health Sciences Wayne State University Detroit Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2220-0081","authenticated-orcid":false,"given":"Michael J.","family":"Rybak","sequence":"additional","affiliation":[{"name":"Anti\u2010Infective Research Laboratory Department of Pharmacy Practice Eugene Applebaum College of Pharmacy and Health Sciences Wayne State University Detroit Michigan USA"},{"name":"Division of Infectious Diseases School of Medicine Wayne State University Detroit Michigan USA"},{"name":"Department of Pharmacy Detroit Receiving Hospital Detroit Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,11,19]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2011.04.005"},{"issue":"1","key":"e_1_2_14_3_1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1086\/653120","article-title":"Treatment of Acinetobacter infections","volume":"51","author":"Fishbain J","year":"2010","journal-title":"Clin Infect Dis"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw829"},{"key":"e_1_2_14_5_1","unstructured":"(CDC) CfDCaP.Antibiotic resistance threats in the United States;2019."},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161213804070285"},{"issue":"10","key":"e_1_2_14_7_1","doi-asserted-by":"crossref","first-page":"ofy241","DOI":"10.1093\/ofid\/ofy241","article-title":"Carbapenem\u2010nonsusceptible Gram\u2010negative pathogens in ICU and non\u2010ICU settings in US hospitals in 2017: a multicenter study","volume":"5","author":"McCann E","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0267-8"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ048"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00093-17"},{"issue":"2","key":"e_1_2_14_11_1","doi-asserted-by":"crossref","first-page":"e01968\u201017","DOI":"10.1128\/AAC.01968-17","article-title":"In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem\u2010nonsusceptible and multidrug\u2010resistant isolates of Gram\u2010negative bacilli collected worldwide in 2014 to 2016","volume":"62","author":"Hackel MA","year":"2018","journal-title":"Antimicrobial Agents Chemother"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0168-2"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0013-7"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2092"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-019-0239-0"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2366"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-1055-2"},{"issue":"12","key":"e_1_2_14_18_1","doi-asserted-by":"crossref","first-page":"7396","DOI":"10.1128\/AAC.01405-16","article-title":"Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa","volume":"60","author":"Ito A","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"e_1_2_14_19_1","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1473-3099(18)30615-7","article-title":"Cefiderocol in context","volume":"18","author":"Huttner A","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"e_1_2_14_20_1","doi-asserted-by":"crossref","first-page":"e01454\u201017","DOI":"10.1128\/AAC.01454-17","article-title":"In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram\u2010negative bacteria","volume":"62","author":"Ito A","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30554-1"},{"key":"e_1_2_14_22_1","first-page":"343","article-title":"Chemistry of cephalosporin antibiotics","volume":"28","author":"Morin RB","year":"1970","journal-title":"Fortschr Chem Org Naturst"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2010.0052"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/10.suppl_C.1"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz826"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2018.06.014"},{"issue":"7","key":"e_1_2_14_27_1","first-page":"509","article-title":"Ceftazidime review","volume":"19","author":"Yost RL","year":"1985","journal-title":"Drug Intell Clin Pharm"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199325020-00002"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2013.04.010"},{"issue":"2","key":"e_1_2_14_30_1","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1369-5274(02)00298-9","article-title":"Active transport of iron and siderophore antibiotics","volume":"5","author":"Braun V","year":"2002","journal-title":"Curr Opin Microbiol"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/bs.aambs.2018.12.001"},{"issue":"2","key":"e_1_2_14_32_1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijantimicag.2018.10.007","article-title":"In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem\u2010non\u2010susceptible Gram\u2010negative bacilli, including serine carbapenemase\u2010 and metallo\u2010beta\u2010lactamase\u2010producing isolates (SIDERO\u2010WT\u20102014 Study)","volume":"53","author":"Kazmierczak KM","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1159\/000487441"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2018.1449508"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03098-15"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02163-17"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.841"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01381-16"},{"key":"e_1_2_14_39_1","unstructured":"ShiamadaJSY KatsubeT WhiteS FukaseH.S\u2010649266 a novel siderophore cephalosporin for gram negative bacterial infection; pharmacokinetics saftey and tolerability in healthy subjects. Abtract F\u20101564 Abstract 54th Intersci Conf. Antimicrobial Agents Chemotherapy;2014."},{"issue":"2","key":"e_1_2_14_40_1","doi-asserted-by":"crossref","first-page":"e01391\u20101","DOI":"10.1128\/AAC.01391-17","article-title":"Population pharmacokinetic analysis of cefiderocol, a parenteral siderophore cephalosporin, in healthy subjects, subjects with various degrees of renal function, and patients with complicated urinary tract infection or acute uncomplicated pyelonephritis","volume":"62","author":"Kawaguchi N","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"e_1_2_14_41_1","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ijantimicag.2017.10.008","article-title":"Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model","volume":"51","author":"Ghazi IM","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02031-18"},{"issue":"9","key":"e_1_2_14_43_1","doi-asserted-by":"crossref","first-page":"e00700\u201017","DOI":"10.1128\/AAC.00700-17","article-title":"Efficacy of cefiderocol against carbapenem\u2010resistant gram\u2010negative bacilli in immunocompetent\u2010rat respiratory tract infection models recreating human plasma pharmacokinetics","volume":"61","author":"Matsumoto S","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"e_1_2_14_44_1","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1093\/jac\/dkz123","article-title":"Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects","volume":"74","author":"Katsube T","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"e_1_2_14_45_1","unstructured":"NakamuraRTS TsujiM YamanoY ShimadaJ.S\u2010649266 a novel siderophore cephalosporin: IV. In vivo efficacy in various murine infection models. 54th Intersci Conf. Antimicrob Agents Chemother.Washington DC;2014."},{"key":"e_1_2_14_46_1","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Institute CaLS","year":"2018"},{"issue":"4","key":"e_1_2_14_47_1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.diagmicrobio.2019.03.003","article-title":"Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron\u2010depleted cation\u2010adjusted Mueller\u2010Hinton broth","volume":"94","author":"Hackel MA","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"e_1_2_14_48_1","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.diagmicrobio.2017.03.011","article-title":"Cefiderocol MIC quality control ranges in iron\u2010depleted cation\u2010adjusted Mueller\u2010Hinton broth using a CLSI M23\u2010A4 multi\u2010laboratory study design","volume":"88","author":"Huband MD","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"e_1_2_14_49_1","unstructured":"Clinical and Laboratory Standards Institute.M100\u2010S25 performance standards for antimicrobial susceptibility testing; twenty\u2010eighth informational supplement;2018."},{"issue":"4","key":"e_1_2_14_50_1","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ijantimicag.2018.11.007","article-title":"In vitro activity of cefiderocol, a siderophore cephalosporin, against Gram\u2010negative bacilli isolated by clinical laboratories in North America and Europe in 2015\u20132016: SIDERO\u2010WT\u20102015","volume":"53","author":"Karlowsky JA","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"e_1_2_14_51_1","unstructured":"TsujiMKK HackelM EcholsR YamanoY SahmD.Cefiderocol (S\u2010649266) susceptibility against globally isolated meropenem non\u2010susceptible Gram\u2010negative bacteria containing serine and metallo\u2010carbapenemase genes. ASM Microbe 2018. 2018. Epub Atlanta GA;2018."},{"key":"e_1_2_14_52_1","doi-asserted-by":"crossref","unstructured":"JacobsMRAA GoodCE.In vitro activity of cefiderocol (S\u2010649266) a siderophore cephalosporin against Enterobacteriaceae with defined extended\u2010spectrum beta\u2010lactamases and carbapenamases. IDWeek. 2018. Epub San Francisco CA;2018.","DOI":"10.1093\/ofid\/ofy210.1182"},{"issue":"12","key":"e_1_2_14_53_1","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s10096-017-3063-z","article-title":"Activity of the novel siderophore cephalosporin cefiderocol against multidrug\u2010resistant Gram\u2010negative pathogens","volume":"36","author":"Dobias J","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"e_1_2_14_54_1","unstructured":"ShieldsRKKE JonesCE.Cefiderocol minimum inhibitory concentrations against ceftazidime\u2010susceptible and resistant carbapenem\u2010resistant Enterobacteriaceae. ASM Microbe 2018. Epub Atlanta GA;2018."},{"key":"e_1_2_14_55_1","doi-asserted-by":"crossref","unstructured":"ItoA NishikawaT IshiiR et al.Mechanism of cefiderocol high MIC mutants obtained in non\u2010clinical for studies. IDWeek 2018. 2018; Abstract 696. Epub San Fancisco CA;2018.","DOI":"10.1093\/ofid\/ofy210.703"},{"issue":"6","key":"e_1_2_14_56_1","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ijantimicag.2018.11.005","article-title":"Stability of cefiderocol against clinically significant broad\u2010spectrum oxacillinases","volume":"52","author":"Poirel L","year":"2018","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"e_1_2_14_57_1","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1093\/jac\/dky317","article-title":"Stability and low induction propensity of cefiderocol against chromosomal AmpC beta\u2010lactamases of Pseudomonas aeruginosa and Enterobacter cloacae","volume":"73","author":"Ito A","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"e_1_2_14_58_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00098-14"},{"issue":"5","key":"e_1_2_14_59_1","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1128\/AAC.48.5.1688-1698.2004","article-title":"Comparative study of the effects of ceftizoxime, piperacillin, and piperacillin\u2010tazobactam concentrations on antibacterial activity and selection of antibiotic\u2010resistant mutants of Enterobacter cloacae and Bacteroides fragilis in vitro and in vivo in mixed\u2010infection abscesses","volume":"48","author":"Stearne LE","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_14_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2011.07.005"},{"key":"e_1_2_14_61_1","unstructured":"KohiraN NakamuraR ItoA et al.Resistance acquisition studies of cefiderocol by serial passage and in vitro pharmacodynamics model under human simulated exposure. ASM Microbe 2018. 2018; Abstract 623. Epub Atlanta GA;2018."},{"key":"e_1_2_14_62_1","volume-title":"S\u2010649266, a novel siderophore cephalosporin: II. Impact of active transport via iron regulated outer membrane proteins on resistance selection","author":"Ito A","year":"2014"},{"key":"e_1_2_14_63_1","unstructured":"Fetroja (Cefiderocol). Package insert.Osaka Japan:Shionogi & Co. Ltd;2019."},{"key":"e_1_2_14_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-018-2458-9"},{"issue":"7","key":"e_1_2_14_65_1","doi-asserted-by":"crossref","first-page":"S559","DOI":"10.1093\/cid\/ciz829","article-title":"Pathogen\u2010focused clinical development to address unmet medical need: cefiderocol targeting carbapenem resistance","volume":"69","author":"Echols R","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"3","key":"e_1_2_14_66_1","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/jac\/dkg097","article-title":"Relationship between beta\u2010lactamase production, outer membrane protein and penicillin\u2010binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii","volume":"51","author":"Fernandez\u2010Cuenca F","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"e_1_2_14_67_1","doi-asserted-by":"publisher","DOI":"10.1086\/511642"},{"key":"e_1_2_14_68_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx176"},{"key":"e_1_2_14_69_1","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2147\/IDR.S148185","article-title":"In vitro activity of colistin mono\u2010 and combination therapy against colistin\u2010resistant Acinetobacter baumannii, mechanism of resistance, and clinical outcomes of patients infected with colistin\u2010resistant A. baumannii at a Thai university hospital","volume":"10","author":"Lertsrisatit Y","year":"2017","journal-title":"Infect Drug Resist"},{"issue":"6","key":"e_1_2_14_70_1","doi-asserted-by":"crossref","first-page":"ofaa18","DOI":"10.1093\/ofid\/ofaa185","article-title":"Cefiderocol for extensively drug\u2010resistant gram\u2010negative bacterial infections: real\u2010world experience from a case series and review of the literature","volume":"7","author":"Zingg S","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"e_1_2_14_71_1","first-page":"ofaa150","article-title":"Case report: successful rescue therapy of extensively drug\u2010resistant Acinetobacter baumannii osteomyelitis with cefiderocol","volume":"7","author":"Dagher M","year":"2020","journal-title":"Infect Dis"},{"issue":"4","key":"e_1_2_14_72_1","doi-asserted-by":"crossref","first-page":"e00948\u201019","DOI":"10.1128\/AAC.00948-19","article-title":"Coinfections of two strains of NDM\u20101\u2010 and OXA\u2010232\u2010coproducing Klebsiella pneumoniae in a kidney transplant patient","volume":"64","author":"Contreras DA","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_14_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy963"},{"key":"e_1_2_14_74_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz318"},{"key":"e_1_2_14_75_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2334"},{"key":"e_1_2_14_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2019.07.006"},{"issue":"9","key":"e_1_2_14_77_1","doi-asserted-by":"crossref","first-page":"e0163271","DOI":"10.1371\/journal.pone.0163271","article-title":"Carbapenem breakpoints for Acinetobacter baumannii group: supporting clinical outcome data from patients with bacteremia","volume":"11","author":"Lee YT","year":"2016","journal-title":"PLoS One"},{"key":"e_1_2_14_78_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02176-12"},{"key":"e_1_2_14_79_1","unstructured":"Cefiderocol meeting of the antimicrobial drugs advisory committee (AMDAC). FDA briefing document."},{"key":"e_1_2_14_80_1","unstructured":"Food and Administration (FDA).FETROJA (cefiderocol) for injection for intravenous use. Initial U.S. Approval;2019. Available fromhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/209445s000lbl.pdf2019. Accessed May 5 2020."},{"key":"e_1_2_14_81_1","unstructured":"Study of S\u2010649266 or best available therapy for the treatment of severe infections caused by carbapenem\u2010resistant Gram\u2010negative pathogens (CREDIBLE \u2013 CR);2018. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02714595?term=cefiderocol&rank=2. Accessed January 1 2020."},{"key":"e_1_2_14_82_1","unstructured":"ItoA KatagiriM IshiokaY RokushimaM HackelM SahmDF TsujiM MakiH SatoT YamanoY.Characterization of isolates showing high MICs to cefiderocol from global surveillance study SIDERO\u2010WT\u20102014. ASM Micorbe 2016; San Francisco CA;2019."}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2476","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2476","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2476","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:02:54Z","timestamp":1761058974000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,19]]},"references-count":81,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1002\/phar.2476"],"URL":"https:\/\/doi.org\/10.1002\/phar.2476","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,19]]},"assertion":[{"value":"2020-11-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}